But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, has announced an unsolicited bid to ...

A major international study led by researchers at University College London has found that semaglutide, the active ingredient ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Oral presentation name: Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function Presenter: Mitchell Steiner, M.D., Chairman, President, and Chief Executive ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Dow Jones Top Company Headlines at 9 PM ET: Amazon Shares Surge on 13% Revenue Jump, Strong Cloud Sales | Apple ... The e-commerce giant said Amazon Web Services is growing at its fastest rate since ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...